Drug intelligence / Profile preview

XL210

Development stage: Preclinical
Lead developer: XL-protein
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

XL210 is a preclinical-stage HER2-targeted imaging agent developed by XL-protein using its proprietary PASylation technology. The molecule consists of a Fab fragment specific for the Human Epidermal Growth Factor Receptor 2 (HER2) genetically fused to a PAS sequence—a conformationally disordered polypeptide comprising Proline, Alanine, and Serine. This modification significantly increases the hydrodynamic volume of the antibody fragment, extending its circulation half-life while maintaining the rapid tissue penetration and high target specificity characteristic of small antibody fragments. XL210 is designed for use in oncology imaging to visualize HER2-positive tumors, potentially aiding in patient stratification and monitoring of HER2-targeted therapies.

Other names: 89Zr-Df-HER2-Fab-PAS20089Zr-labeled PASylated anti-HER2 Fab89Zr·Df-HER2-Fab-PAS200HER2-Fab-PAS200HER-2-Fab-PAS200HER 2-Fab-PAS200

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on XL210.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL210.